Deutsche Bank AG Sells 9,146 Shares of United Therapeutics Corporation (NASDAQ:UTHR)

Key Points

• Deutsche Bank AG has reduced its stake in United Therapeutics Corporation by 6.4%, holding 134,483 shares valued at approximately $41.5 million after selling 9,146 shares.
• During the fourth quarter, other institutional investors, such as Envestnet Asset Management and Barclays PLC, also increased their positions in United Therapeutics, leading to a combined 94.08% institutional ownership of the stock.
• United Therapeutics reported earnings of $6.41 per share in its latest quarterly report, missing analyst estimates of $6.80 and achieving a revenue of $798.6 million, falling short of expectations of $802.13 million.

Deutsche Bank AG decreased its position in United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 6.4% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 134,483 shares of the biotechnology company's stock after selling 9,146 shares during the period. Deutsche Bank AG owned approximately 0.30% of United Therapeutics worth $41,457,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in UTHR. XTX Topco Ltd acquired a new position in United Therapeutics in the 1st quarter worth $313,000. Allianz Asset Management GmbH boosted its stake in United Therapeutics by 96.9% in the 1st quarter. Allianz Asset Management GmbH now owns 67,576 shares of the biotechnology company's stock worth $20,832,000 after purchasing an additional 33,254 shares during the period. LPL Financial LLC boosted its stake in United Therapeutics by 77.3% in the 1st quarter. LPL Financial LLC now owns 25,246 shares of the biotechnology company's stock worth $7,783,000 after purchasing an additional 11,007 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its stake in United Therapeutics by 11.4% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,678 shares of the biotechnology company's stock worth $1,129,000 after purchasing an additional 376 shares during the period. Finally, Concurrent Investment Advisors LLC acquired a new position in United Therapeutics in the 1st quarter worth $227,000. Institutional investors and hedge funds own 94.08% of the company's stock.

Analyst Upgrades and Downgrades

UTHR has been the topic of several analyst reports. Wells Fargo & Company cut their price target on shares of United Therapeutics from $314.00 to $295.00 and set an "equal weight" rating on the stock in a research report on Thursday, July 31st. Bank of America dropped their target price on shares of United Therapeutics from $321.00 to $315.00 and set a "neutral" rating on the stock in a report on Wednesday, June 11th. Morgan Stanley lowered their price target on shares of United Therapeutics from $348.00 to $328.00 and set an "equal weight" rating on the stock in a report on Thursday, July 10th. Cantor Fitzgerald restated an "overweight" rating on shares of United Therapeutics in a research report on Thursday. Finally, Wall Street Zen lowered shares of United Therapeutics from a "strong-buy" rating to a "buy" rating in a research report on Friday, May 2nd. Four equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $382.00.

Insider Activity at United Therapeutics

In other news, Director Richard Giltner sold 3,036 shares of the firm's stock in a transaction on Tuesday, June 24th. The shares were sold at an average price of $289.60, for a total transaction of $879,225.60. Following the completion of the transaction, the director owned 19,384 shares of the company's stock, valued at approximately $5,613,606.40. This trade represents a 13.54% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Paul A. Mahon sold 11,000 shares of the firm's stock in a transaction on Thursday, June 12th. The shares were sold at an average price of $279.96, for a total transaction of $3,079,560.00. Following the transaction, the executive vice president directly owned 36,781 shares of the company's stock, valued at $10,297,208.76. The trade was a 23.02% decrease in their position. The disclosure for this sale can be found here. Insiders sold 81,681 shares of company stock worth $24,618,359 in the last 90 days. 10.30% of the stock is currently owned by company insiders.

United Therapeutics Trading Up 0.8%

NASDAQ:UTHR traded up $2.34 on Thursday, hitting $312.06. The company had a trading volume of 586,994 shares, compared to its average volume of 676,653. The stock has a market capitalization of $14.08 billion, a price-to-earnings ratio of 12.18, a PEG ratio of 4.69 and a beta of 0.57. The firm has a 50 day moving average of $295.25 and a two-hundred day moving average of $309.63. United Therapeutics Corporation has a 52 week low of $266.98 and a 52 week high of $417.82.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings data on Wednesday, July 30th. The biotechnology company reported $6.41 EPS for the quarter, missing the consensus estimate of $6.80 by ($0.39). The company had revenue of $798.60 million during the quarter, compared to the consensus estimate of $802.13 million. United Therapeutics had a net margin of 40.36% and a return on equity of 18.73%. United Therapeutics's revenue for the quarter was up 11.7% on a year-over-year basis. During the same period in the previous year, the company earned $5.85 EPS. As a group, equities analysts forecast that United Therapeutics Corporation will post 24.48 EPS for the current year.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.